

## Info Sheet for Technical description

No. 0011 - 2

### Organization

\* Mandatoty fields

Name of Organization*	REPROCELL Inc.	
Address, City, States, Zip, Country*	MetLife Shin-yokohama Bldg. 9F, 3-8-11 Shin-yokohama, Kohoku-ku, Yokohama, Kanagawa 222-0033, Japan	
URL	<a href="https://www.reprocell.com/">https://www.reprocell.com/</a>	
Brief Descriptions of Organization* (Approx. 100 words)	1) Research Support Business Manufacture and sale of reagents for iPS cell research Provision of drug discovery support services (i.e., establishment of iPS cell lines, CRO services, etc.) Provision of biological samples Provision of genetic analysis services	
Contact address	Name*	
	Department* / Position	
	E-mail* / TEL	

### What kind of technology do you want to offer? \*

- A.** Clinical Development Pipelines → Please see **Sheet [A]**
- B.** Regenerative Medicine-related Consumables / Instruments / Materials / CDMO Services etc. → Please see **Sheet [B]**
- C.** Platform Technologies(\*) that are not included in the above (Group B) → Please see **Sheet [C]**
- \* Peripheral technologies that contribute to a significant improvement in productivity throughout the value chain of pharmaceuticals, from research and development to manufacturing and ultimately market launch.

### If you agree to the following, please check "Yes" below. \*

The technologies introduced in this 'Info Sheet' are in the public domain, as they have been published in research papers or have related patent applications.

- Yes

### Do you have any collaborations/partnerships with pharmaceutical companies?

- Yes
- No

### If you have already received funding from VCs or other sources, up to which stage has the investment round progressed?

- Angel / Seed (including AMED/JST grants)
- Series A
- Series B
- Series C
- Series D or further advanced stages

### Do you agree to leave your presentation materials at FIRM hands and entrust us to make use of them for the purpose of promoting your partnering opportunities? \*

Options*	Comments
<input checked="" type="checkbox"/> Yes	
<input type="checkbox"/> No	

Filled in by\*

Date\*

Mitsuru Inamura
09/22/2023

<b>Info Sheet for Technical overview</b>
--

No. 0011 - 2

\* Mandatoty fields

**Title\***

<b>Q-cell GPR Cell Therapy</b>
--------------------------------

**Development Phase\***

- |   |  |   |
|---|--|---|
| <input type="checkbox"/> Basic Research           | <input type="checkbox"/> Drug Discovery            | <input checked="" type="checkbox"/> Pre-Clinical    |
| <input type="checkbox"/> Clinical Trial (Phase I) | <input type="checkbox"/> Clinical Trial (Phase II) | <input type="checkbox"/> Clinical Trial (Phase III) |
| <input type="checkbox"/> Review                   | <input type="checkbox"/> Others                    |   |

**Disease Area\***

- |  |  |   |
|--|--|---|
| <input type="checkbox"/> Cancer          | <input checked="" type="checkbox"/> Central nervous system | <input type="checkbox"/> Ophthalmology  |
| <input type="checkbox"/> Musculoskeletal | <input type="checkbox"/> Endocrine / Metabolism            | <input type="checkbox"/> Cardiovascular |
| <input type="checkbox"/> Urogenital      | <input type="checkbox"/> Digestive organ                   | <input type="checkbox"/> Blood          |
| <input type="checkbox"/> Infection       | <input type="checkbox"/> Dermatology                       | <input type="checkbox"/> Immunity       |
| <input type="checkbox"/> Otolaryngology  | <input type="checkbox"/> Respiratory                       | <input type="checkbox"/> Others         |

**Description\***

REPROCELL's iPSC-GRPs are the first and only human glial-restricted progenitor (GRP) cell therapeutic. They are derived from induced pluripotent stem cells (iPSCs) which provide an unlimited source of robust GRPs for therapeutic use.

GRPs are progenitor cells that differentiate into astrocytes and oligodendrocytes following transplantation. Astrocytes provide an environment for the normal function of nerve cells, while oligodendrocytes form the myelin that surrounds the axons of nerve cells, aiding electrical signaling. So far, GRPs have been shown to prolong the survival time and observed myelination in mouse models.

Based on the results of preclinical studies, iPSC-GRPs are expected to be effective in various CNS diseases, including demyelinating and neurodegenerative conditions (Figure 2). The FDA has now completed the Investigative New Drug (IND) application for amyotrophic lateral sclerosis (ALS) and transverse myelitis (TM) patients; REPROCELL therefore plans to focus our efforts in these areas before branching out to other CNS disorders.

Currently, REPROCELL iPSC-GRP research is focused on the treatment of ALS and TM, two rare CNS diseases that affect the quality of life for thousands of patients globally. It is hoped that the clinical introduction of new therapeutics, such as iPSC-GRPs and Q-Cells®, will improve the quality and length of life for these patients.

**Filled in by\***

Mitsuru Inamura

**Date\***

09/22/2023